One Size Doesn't Fit All

12.11.13 | By

Over the weekend, the Washington Post ran a story about the price of prescription medicines offered through the Medicare Part B program, a benefit that provides coverage for outpatient administered medicines.

Conversations on Neglected Tropical Diseases

12.10.13 | By

According to the World Health Organization (WHO), neglected tropical diseases (NTDs) affect more than 1 billion people around the world and are prevalent in more than 149 countries.

The Value of Patient Education

12.06.13 | By

It’s a basic tenant of our industry: the well-being of patients is one of the most important pillars of the biopharmaceutical industry. Whether in the creation of new medications or updating information about current medicine, our industry strives to educate patients safely and transparently on the status of treatments that could change their lives.

Medicare Part D Accomplishments

12.06.13 | By

Birthdays provide a great opportunity to look back and reflect on accomplishments made along the way. On December 8, 2003, the Medicare Prescription Drug, Improvement, and Modernization Act, which created Medicare Part D, was signed into law. Since its enactment 10 years ago, the program has racked up an impressive track record. Here are just a few of its accomplishments:

PhRMA Commends House of Representatives

Washington, D.C. (December 5, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement on H.R. 3309, the Innovation Act, as passed by the U.S. House of Representatives today: 

“PhRMA commends the House of Representatives for its work to curb abusive patent litigation.

Transformative Technology to Treat Hepatitis C

12.05.13 | By

If you follow PhRMA and especially the Catalyst, you’ll notice we spend a lot of time focusing on how innovative medicines can be a great, transformative technology. A great example includes this morning’s NPR Morning Edition, reporting on new medicines to treat Hepatitis C, soon to be approved by the FDA. 

Clinical Trials in Alabama

12.05.13 | By

Biopharmaceutical research companies have already conducted more than 3,400 clinical trials of new medicines in Alabama since 1999.  And Governor Robert Bentley made clear yesterday his desire to see the valuable partnership between the biopharmaceutical sector and his state’s research institutions continue well into the future.

Implementing Responsible Clinical Trial Data Sharing

12.04.13 | By

Earlier this year, PhRMA member companies, along with member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced new commitments

Stopping Counterfeit Medicines Online

12.02.13 | By

Fake medicines put patients and the public at risk. In the U.S. almost all fake medicines enter the drug supply through purchases over the internet. This is a pervasive problem all around the world.

A Time to Give Thanks

11.22.13 | By

With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.

Pages

Subscribe to RSS - Opinion